Actinogen Medical (ASX: ACW) — Company Overview, News & Financial Data
Actinogen Medical is a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases.
Actinogen Medical
Actinogen Medical is a clinical-stage biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases associated with elevated brain cortisol levels. The company's lead drug candidate is Xanamem (emestedastat), an orally administered small molecule designed to inhibit the 11β-HSD1 enzyme and reduce tissue cortisol production in the brain. Actinogen conducts clinical trials evaluating Xanamem for cognitive impairment in early Alzheimer's disease, major depressive disorder, and cognitive and behavioral symptoms in fragile X syndrome. The company advances its therapeutic pipeline through international clinical research programs and academic collaborations.
Snapshot
Operations
Products and/or services of Actinogen Medical
- Alzheimer's Disease Clinical Development: Conducting the Phase 2b/3 XanaMIA clinical trial evaluating oral Xanamem (emestedastat) to inhibit the 11β-HSD1 enzyme, lower central nervous system cortisol levels, and slow cognitive decline in patients with early Alzheimer's disease.
- Major Depressive Disorder Pipeline: Developing Xanamem as an adjunctive oral treatment in Phase 2 clinical trials targeting cognitive impairment and depressive symptoms in patients diagnosed with major depressive disorder.
- Fragile X Syndrome Program: Evaluating Xanamem in clinical research programs addressing anxiety, sleep disturbances, and behavioral symptoms associated with Fragile X Syndrome, a genetic neurodevelopmental condition.
- 11β-HSD1 Enzyme Inhibition Platform: Researching and refining small molecule therapeutics that block 11β-hydroxysteroid dehydrogenase type 1 enzyme activity to regulate intracellular cortisol production across neurodegenerative and neuropsychiatric indications.
Actinogen Medical executive team
- Steven G. GourlayMD, CEO & Director
- William Edward SouterChief Financial Officer
- Dana C. HiltChief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
- Andrew B. UdellChief Commercial Officer
- Michael RobertsHead of Investor Relations & Corporate Communications
- Paul Edward RolanHead of Clinical Pharmacology & Lead Physician and Depression
- Fujun LiHead of Manufacturing
- Peter Gordon WebseCompany Secretary
Latest news about Actinogen Medical
Recent announcements
What Actinogen Medical (ACW) has told the market, newest first.
- Notification of buy-back - ACW
- AGM date and closing date for director nominations
- Application for quotation of securities - ACW
- ACW third positive XanaMIA trial data committee reviewPrice sensitive
Key financials
Reported results for Actinogen Medical, in AUD.
- Market cap
- 158.8M
- Revenue (TTM)
- 12.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- 0.0
- Dividend yield
- —
- Profit margin
- -121.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -28.1M | -15.4M | |
| 5.5M | -14.9M | -14.7M | |
| 9.9M | -12.8M | -13M | |
| 4.9M | -15.9M | -10.8M |